Leerink initiated coverage of Summit Therapeutics (SMMT) with an Underperform rating and $12 price target Ivonescimab, Summit Therapeutics’ VEGF-A/PD-1 bispecific, is a strong product and Summit leadership deserves credit for licensing ex-China rights to the bispecific from Akeso long before the clinical outcomes were clearly compelling, the firm says. However, Leerink does not believe Ivonescimab is the next Keytruda. For the firm, consensus estimates assume an unrealistic share of the current anti-PD(L)1 total addressable market, given the intense and heterogenous competitive landscape, and compared to the PD-(L)1 era, higher threshold for clinical success, regulatory approval, and uptake.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Optimistic Outlook for Summit Therapeutics: Buy Rating Affirmed Despite OS Miss in HARMONi Trial
- Bristol deal takes out ‘key’ potential buyer of Summit Therapeutics, says Truist
- Biotech Alert: Searches spiking for these stocks today
- SMMT, MTDR, FTAI: 3 High-Potential Russell 2000 Stocks with Strong Buy Ratings
- Positive Buy Rating for Summit Therapeutics Driven by Promising Ivonescimab Trial Results
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue